Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas

Front Oncol. 2021 Oct 6:11:774861. doi: 10.3389/fonc.2021.774861. eCollection 2021.

Shreya Mehta^{1

2}, Nazim Bhimani³, Anthony J Gill^{1

2

4

5

6}, Jaswinder S Samra^{1

3

5}, Sumit Sahni^{1

2

5}, Anubhav Mittal^{1

3

5}

¹ Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
² Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
³ Upper Gastro Intestinal (GI) Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, NSW, Australia.
⁴ Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW, Australia.
⁵ Australian Pancreatic Centre, Sydney, NSW, Australia.
⁶ NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW, Australia.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.708963.].

Keywords: Ca-125 and Ca 19-9; S100A4; diagnostic biomarkers; pancreatic ductal adenocarcinoma; prognostic biomarkers; survival analysis.